A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Name: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Published: 2011
License: Public Domain

Seagen Inc. · 2011

ClinicalTrials.gov · Datasets · License: Public Domain · 2011

Open Source ↗

antibodies antigens drug-therapy lymphoma monoclonal t-cell

lymphoma, large-cell, anaplastic, lymphoma, nk-cell, lymphoma, t-cell, antibodies, monoclonal, antibody-drug conjugate, antigens, cd30, drug therapy, hematologic diseases, lymphoma, monomethyl auristatin e, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Related documents